LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Search

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

67.79 -6.96

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.52

Max

69.01

Belangrijke statistieken

By Trading Economics

Inkomsten

81M

105M

Verkoop

17M

161M

K/W

Sectorgemiddelde

20.524

49.8

Winstmarge

65.551

Werknemers

898

EBITDA

-916K

32M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+92.81% upside

Dividenden

By Dow Jones

Volgende Winsten

29 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.2B

3.4B

Vorige openingsprijs

74.75

Vorige sluitingsprijs

67.79

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Peer Vergelijking

Prijswijziging

TransMedics Group Inc Prognose

Koersdoel

By TipRanks

92.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 130.8 USD  92.81%

Hoogste 175 USD

Laagste 85 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor TransMedics Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technische score

By Trading Central

92.43 / 94.18Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat